Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.42 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.40 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.40 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4995450 | 0.87 | EGLN3 (0.43) | EGLN1EGLN3OGFOD1EGLN2HIF1AN | |
| SCHEMBL5000019 | 0.85 | EGLN1 (0.43) | EGLN1EGLN3OGFOD1EGLN2HIF1AN | |
| SCHEMBL4994439 | 0.84 | EGLN3 (0.44) | EGLN1EGLN3OGFOD1EGLN2HIF1AN | |
| SCHEMBL4992314 | 0.84 | EGLN1 (0.44) | EGLN1EGLN3OGFOD1EGLN2HIF1AN | |
| SCHEMBL4988793 | 0.82 | EGLN3 (0.46) | EGLN1EGLN3OGFOD1EGLN2HIF1AN | |
| SCHEMBL4992269 | 0.82 | EGLN1 (0.45) | EGLN1EGLN3OGFOD1EGLN2HIF1AN | |
| SCHEMBL4994532 | 0.81 | EGLN1 (0.43) | EGLN1EGLN3OGFOD1EGLN2HIF1AN | |
| SCHEMBL4737006 | 0.80 | EGLN1 (0.52) | EGLN1EGLN3OGFOD1EGLN2HIF1AN | |
| SCHEMBL4992312 | 0.80 | EGLN3 (0.47) | EGLN1EGLN3OGFOD1EGLN2HIF1AN | |
| SCHEMBL4988740 | 0.78 | EGLN1 (0.41) | EGLN1EGLN3OGFOD1EGLN2HIF1AN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | claimed |
| WO-2008089051-A1 | N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | EGLN1 5/4885EGLN3 3/4885OGFOD1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.